General
Preferred name
LOPINAVIR
Synonyms
ABT-378 ()
Lopinavir (ABT-378) ()
LOPINAVIR MONOHYDRATE ()
Lopinavir, (s-(2s,4s,5s))- ()
Aluviran ()
A-157378.0 ()
Lopinavir component of kaletra ()
A-157378-0 ()
Lopinavirum ()
Koletra ()
Lopinavir- ()
P&D ID
PD009457
CAS
192725-17-0
Tags
available
drug
Approved by
EMA
FDA
First approval
2000
Drug indication
Severe acute respiratory syndrome (SARS)
HIV infection
Human immunodeficiency virus infection
Middle East Respiratory Syndrome (MERS)
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS
This drug is a protease inhibitor. Inhibiting HIV-1 protease (responsible for protein cleavage), results in selectively inhibiting the cleavage of HIV gag and gag-pol polyproteins, thereby preventing viral maturation.
DESCPRITION
An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.
DESCRIPTION
Lopinavir is an antiretroviral protease inhibitor. It has subsequently been discovered to exhibit antiviral activity against human papilloma virus (HPV), and to inhibit MERS-CoV replication in vitro . Antiviral activity against SARS-CoV-2 has been explored , however lopinavir/ritonavir therapy provided no benefit in hospitalised COVID-19 patients .
(GtoPdb)
DESCRIPTION
Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity[1][2]. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 ¦ÌM[3].
PRICE
29
DESCRIPTION
Potent, selective and reversible DCN1-UBC12 interaction inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
Lopinavir is a potent HIV protease inhibitor. It is used in combination with other antiretrovirals in the treatment of HIV-1 infection.
(Enamine Bioactive Compounds)
DESCRIPTION
Lopinavir (ABT-378) is a peptidomimetic HIV protease inhibitor effective against HIV protease with the Val 82 mutation. It is less affected by serum protein binding compared to the structurally related drug ritonavir.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
11
Compound Sets
27
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
49
Molecular Weight
628.36
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
4
Rotatable Bonds
15
Ring Count
4
Aromatic Ring Count
3
cLogP
4.33
TPSA
120.0
Fraction CSP3
0.43
Chiral centers
4.0
Largest ring
6.0
QED
0.2
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
HIV Protease
SARS-CoV
HIV protease inhibitor
COVID-19,HIV Protease
MOA
Inhibitor
HIV Protease inhibitor
Indication
human immunodeficiency virus (HIV-1)
Therapeutic Class
Anti-HIV Agents
Antiviral Agents
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Metabolic Enzyme/Protease
Source data
